Regulus Therapeutics’ (RGLS) “Buy” Rating Reiterated at Canaccord Genuity Group

Canaccord Genuity Group reissued their buy rating on shares of Regulus Therapeutics (NASDAQ:RGLS) in a research note issued to investors on Monday,Benzinga reports. Canaccord Genuity Group currently has a $28.00 target price on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Regulus Therapeutics in a report on Friday, March 14th.

Regulus Therapeutics Trading Up 1.4 %

Shares of Regulus Therapeutics stock opened at $1.40 on Monday. Regulus Therapeutics has a twelve month low of $0.83 and a twelve month high of $3.00. The stock has a market capitalization of $91.70 million, a P/E ratio of -1.31 and a beta of 1.42. The business’s fifty day moving average price is $1.27 and its 200 day moving average price is $1.45.

Regulus Therapeutics (NASDAQ:RGLS) last issued its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.20). During the same period last year, the firm posted ($0.40) earnings per share. As a group, sell-side analysts predict that Regulus Therapeutics will post -0.88 EPS for the current year.

Insiders Place Their Bets

In other Regulus Therapeutics news, CEO Joseph P. Hagan sold 115,290 shares of the business’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $1.26, for a total transaction of $145,265.40. Following the transaction, the chief executive officer now owns 222,572 shares in the company, valued at $280,440.72. The trade was a 34.12 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Preston Klassen sold 31,445 shares of Regulus Therapeutics stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $1.26, for a total value of $39,620.70. Following the sale, the insider now directly owns 36,055 shares in the company, valued at approximately $45,429.30. The trade was a 46.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 223,998 shares of company stock worth $282,237 over the last quarter. 4.35% of the stock is owned by corporate insiders.

Institutional Trading of Regulus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Jane Street Group LLC purchased a new stake in shares of Regulus Therapeutics during the third quarter worth about $46,000. PEAK6 LLC bought a new stake in Regulus Therapeutics in the fourth quarter valued at about $95,000. Velan Capital Investment Management LP bought a new stake in Regulus Therapeutics in the fourth quarter valued at about $111,000. JPMorgan Chase & Co. increased its holdings in Regulus Therapeutics by 193.4% in the third quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 52,059 shares during the last quarter. Finally, Barclays PLC increased its holdings in Regulus Therapeutics by 285.2% in the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 62,549 shares during the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.